Drugs / GSK3965193
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05330455 | Apr 2022 → May 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3965193 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05330455 ↗ |
| Known as | GSK3965193B FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068553 ↗ |
| Modality | Small molecule | — CHEMBL6068553 ↗ |
| Route | Oral | “GSK3965193 oral tablets” NCT05330455 ↗ |